BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...joins as VP, discovery and innovation. Williams was SVP, global technical development and operations at OvaScience...
BioCentury | Dec 14, 2018
Company News

Millendo, OvaScience merge, raise $50M

...from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc....
...congenital adrenal hyperplasia (CAH). It is a selective inhibitor of sterol O-acyltransferase 1 (SOAT1; ACAT1). OvaScience...
...options holders of the former private Millendo will own 63.3% of the combined company, while OvaScience...
BioCentury | Dec 7, 2018
Company News

Millendo, OvaScience merge, raise $50M

...from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc....
...congenital adrenal hyperplasia (CAH). It is a selective inhibitor of sterol O-acyltransferase 1 (SOAT1; ACAT1). OvaScience...
...options holders of the former private Millendo will own 63.3% of the combined company, while OvaScience...
BioCentury | Aug 10, 2018
Company News

Millendo, OvaScience reverse merging

...Fertility company OvaScience Inc. (NASDAQ:OVAS) will reverse-merge with endocrine play Millendo Therapeutics Inc. (Ann Arbor, Mich.) in...
...of at least $70 million, and keep Millendo's name and trade on NASDAQ as MLND. OvaScience...
...this quarter to treat congenital adrenal hyperplasia. The merger is slated to close next quarter. OvaScience Inc....
BioCentury | Aug 4, 2017
Finance

Increasing Homology

...head of research and early development until 2013, when he became president and CSO of OvaScience Inc....
BioCentury | Jun 30, 2017
Company News

Management tracks

...Tokyo:4901) acquired in 2015. Deans was CSO at Rubius Therapeutics Inc. (Cambridge, Mass.). Fertility company OvaScience Inc....
BioCentury | Jun 22, 2017
Clinical News

OvaScience completes enrollment in pilot trial of OvaPrime

...include hormone level change, development of new follicles, egg maturation, pre-implantation genetic screening and pregnancy. OvaScience...
...OvaPrime is a fertility treatment that uses EggPC cells to increase a woman's egg reserve. OvaScience Inc....
...and pregnancy Status: Completed pilot trial enrollment Milestone: Interim pilot trial data (year end 2017) Alicia Parker OvaPrime OvaScience Inc....
BioCentury | Jan 7, 2017
Company News

Management tracks

...CFO. He succeeds George Elston, who left the company. Young was CFO and treasurer at OvaScience Inc....
BioCentury | Jan 6, 2017
Company News

OvaScience endocrine/metabolic news

...President and CEO Harald Stock and COO Paul Chapman will step down. Early last year, OvaScience...
...The company said it plans to increase focus on development of OvaPrime and OvaTure . OvaScience...
...$58.6 million. OvaScience could not be reached for details. OvaScience Inc. (NASDAQ:OVAS), Cambridge, Mass. Business: Endocrine/Metabolic Meghan Sullivan OvaPrime OvaTure OvaScience Augment...
BioCentury | Dec 23, 2016
Company News

Management tracks

...As part of a restructuring, fertility company OvaScience Inc. (NASDAQ:OVAS) said President and CEO Harald Stock and...
...NASDAQ:OVAS) said President and CEO Harald Stock and COO Paul Chapman will leave the company. OvaScience...
Items per page:
1 - 10 of 68
BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...joins as VP, discovery and innovation. Williams was SVP, global technical development and operations at OvaScience...
BioCentury | Dec 14, 2018
Company News

Millendo, OvaScience merge, raise $50M

...from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc....
...congenital adrenal hyperplasia (CAH). It is a selective inhibitor of sterol O-acyltransferase 1 (SOAT1; ACAT1). OvaScience...
...options holders of the former private Millendo will own 63.3% of the combined company, while OvaScience...
BioCentury | Dec 7, 2018
Company News

Millendo, OvaScience merge, raise $50M

...from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc....
...congenital adrenal hyperplasia (CAH). It is a selective inhibitor of sterol O-acyltransferase 1 (SOAT1; ACAT1). OvaScience...
...options holders of the former private Millendo will own 63.3% of the combined company, while OvaScience...
BioCentury | Aug 10, 2018
Company News

Millendo, OvaScience reverse merging

...Fertility company OvaScience Inc. (NASDAQ:OVAS) will reverse-merge with endocrine play Millendo Therapeutics Inc. (Ann Arbor, Mich.) in...
...of at least $70 million, and keep Millendo's name and trade on NASDAQ as MLND. OvaScience...
...this quarter to treat congenital adrenal hyperplasia. The merger is slated to close next quarter. OvaScience Inc....
BioCentury | Aug 4, 2017
Finance

Increasing Homology

...head of research and early development until 2013, when he became president and CSO of OvaScience Inc....
BioCentury | Jun 30, 2017
Company News

Management tracks

...Tokyo:4901) acquired in 2015. Deans was CSO at Rubius Therapeutics Inc. (Cambridge, Mass.). Fertility company OvaScience Inc....
BioCentury | Jun 22, 2017
Clinical News

OvaScience completes enrollment in pilot trial of OvaPrime

...include hormone level change, development of new follicles, egg maturation, pre-implantation genetic screening and pregnancy. OvaScience...
...OvaPrime is a fertility treatment that uses EggPC cells to increase a woman's egg reserve. OvaScience Inc....
...and pregnancy Status: Completed pilot trial enrollment Milestone: Interim pilot trial data (year end 2017) Alicia Parker OvaPrime OvaScience Inc....
BioCentury | Jan 7, 2017
Company News

Management tracks

...CFO. He succeeds George Elston, who left the company. Young was CFO and treasurer at OvaScience Inc....
BioCentury | Jan 6, 2017
Company News

OvaScience endocrine/metabolic news

...President and CEO Harald Stock and COO Paul Chapman will step down. Early last year, OvaScience...
...The company said it plans to increase focus on development of OvaPrime and OvaTure . OvaScience...
...$58.6 million. OvaScience could not be reached for details. OvaScience Inc. (NASDAQ:OVAS), Cambridge, Mass. Business: Endocrine/Metabolic Meghan Sullivan OvaPrime OvaTure OvaScience Augment...
BioCentury | Dec 23, 2016
Company News

Management tracks

...As part of a restructuring, fertility company OvaScience Inc. (NASDAQ:OVAS) said President and CEO Harald Stock and...
...NASDAQ:OVAS) said President and CEO Harald Stock and COO Paul Chapman will leave the company. OvaScience...
Items per page:
1 - 10 of 68